Inhibitory effects of asiatic acid and CPT-11 on growth of HT-29 cells

Journal of Medical Investigation

Volumn 52, Issue 1-2, 2005, Pages 65-73

  Bunpo, Piyawan ^a,b   Kataoka, Keiko ^a   Arimochi, Hideki ^a   Nakayama, Haruyuki ^a   Kuwahara, Tomomi ^a   Vinitketkumnuen, Usanee ^b   Ohnishi, Yoshinari ^a  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

^b Faculty of Medicine Chiang Mai University   (Thailand)

Author keywords

Apoptosis; Asiatic acid; Combination; CPT 11; Cytotoxicity

Indexed keywords

ANNEXIN; ANTINEOPLASTIC AGENT; ASIATIC ACID; CASPASE 3; CASPASE 3 INHIBITOR; DNA FRAGMENT; IRINOTECAN; PROTEIN BCL 2; PROTEIN BCL XL; TRITERPENE DERIVATIVE; CAMPTOTHECIN; CASP3 PROTEIN, HUMAN; CASPASE; DRUG DERIVATIVE; TRITERPENE;

APOPTOSIS; ARTICLE; CANCER INHIBITION; CARCINOMA CELL; COLON ADENOCARCINOMA; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOSE RESPONSE; DRUG CYTOTOXICITY; DRUG MECHANISM; DRUG POTENTIATION; DRUG SENSITIVITY; ENZYME ACTIVATION; HUMAN; HUMAN CELL; MEDICINAL PLANT; SIDE EFFECT; CELL DIVISION; CELL STRAIN HT29; COLON TUMOR; DRUG EFFECT; ENZYMOLOGY; METABOLISM; PATHOLOGY;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; CAMPTOTHECIN; CASPASE 3; CASPASES; CELL DIVISION; COLONIC NEOPLASMS; HT29 CELLS; HUMANS; TRITERPENES;

EID: 15544366910     PISSN: 13431420     EISSN: None     Source Type: Journal    
DOI: 10.2152/jmi.52.65     Document Type: Article

References (51)

1. Babu TD, Kuttan G, Padikkala J: Cytotoxic and anti-tumour properties of certain taxa of Umbelliferae with special reference to Centella asiatica (L.) Urban. J Ethnopharmacol 48: 53-57, 1995
2. Bunpo P, Kataoka K, Arimochi H, Nakayama H, Kuwahara T, Bando Y, Izumi K, Vinitketkumnuen U, Ohnishi Y: Inhibitory effects of Centella asiatica on azoxymethane-induced aberrant crypt focus formation and carcinogenesis in the intestines of F 344 rats. Food Chem Toxicol, 42: 1987-1997, 2004
3. Cha HJ, Park MT, Chung HY, Kim ND, Sato H, Seiki M, Kim KW: Ursolic acid-induced down-regulation of MMP-9 gene is mediated through the nuclear translocation of glucocorticoid receptor in HT1080 human fibrosarcoma cells. Oncogene 16: 771-778, 1998
4. Sohn KH, Lee HY, Chung HY, Young HS, Yi SY, Kim KW: Anti-angiogenic activity of triterpene acids. Cancer Lett 94: 213-218, 1995
5. Novotny L, Vachalkova A, Biggs D: Ursolic acid: an anti-tumorigenic and chemopreventive activity. Minireview. Neoplasma 48: 241-246, 2001
6. Choi YH, Baek JH, Yoo MA, Chung HY, Kim ND, Kim KW: Induction of apoptosis by ursolic acid through activation of caspases and down-regulation of c-IAPs in human prostate epithelial cells. Int J Oncol 17: 565-571, 2000
7. Kim DK, Baek JH, Kang CM, Yoo MA, Sung JW, Chung H, Kim ND, Choi YH, Lee SH, Kim KW: Apoptotic activity of ursolic acid may correlate with the inhibition of initiation of DNA replication. Int J Cancer 87: 629-636, 2000
8. Andersson D, Liu JJ, Nilsson A, Duan RD: Ursolic acid inhibits proliferation and stimulates apoptosis in HT29 cells following activation of alkaline sphingomyelinase. Anticancer Res 23: 3317-3322, 2003
9. 2+ release and enhanced expression of p 53 in HepG2 human hepatoma cells. Cancer Lett 186: 83-91, 2002
10. Vogelstein B, Lane D, Levin AJ: Surfing the p53 network. Nature 408: 307-310, 2000
11. Cheng EH, Wei MC, Weiler S, Flavell RA, Mak TW, Lindsten T, Korsmeyer SJ: BCL-2, BCL-X (L) sequester BH3 domain only molecules preventing BAX-and BAK-mediated mitochondrial apoptosis. Mol Cell 8: 705-711, 2001
12. Green DR, Reed JC: Mitochondria and apoptosis. Science 281: 1309-1312, 1998
13. Antonsson B, Martinou JC: The Bcl-2 protein family. Exper Cell Res 256: 50-57, 2000
14. Krajewska M, Moss SF, Krajewski S, Song K, Holt PR, Reed JC: Elevated expression of Bcl-X and reduced Bak in primary colorectal adenocarcinomas. Cancer Res 56: 2422-2427, 1996
15. Ferlini C, Raspaglio G, Mozzetti S, Distefano M, Filippetti F, Martinelli E, Ferrandina G, Gallo D, Ranelletti FO, Scambia G: Bcl-2 down-regulation is a novel mechanism of paclitaxel resistance. Mol Pharmacol 64: 51-58, 2003
16. Hsu MJ, Cheng JS, Huang HC: Effect of saikosaponin, a triterpene saponin, on apoptosis in lymphocytes: association with c-myc, p53, and bcl-2 mRNA. Br J Pharmacol 131: 1285-1293, 2000
17. Liu WK, Xu SX, Che CT: Anti-proliferative effect of ginseng saponins on human prostate cancer cell line. Life Sci 67: 1297-1306, 2000
18. Kunimoto T, Nitta K, Tanaka T, Uehara N, Baba H, Takeuchi M, Yokokura T, Sawada S, Miyasaka T, Mutai M: Antitumor activity of 7-ethyl-10-[4-(1- piperidino)-1-piperidino]carbonyloxy-camptothecin, a novel water-soluble derivative of camptothecin, against murine tumors. Cancer Res 47: 5944-5948, 1987
19. Kjeldsen E, Svejstrup JQ, Gromova II, Alsner J, Westergaard O: Camptothecin inhibits both the cleavage and religation reactions of eukaryotic DNA topoisomerase I. J Mol Biol 228: 1025-1030, 1992
20. Chitapanarux I, Tonusin A, Sukthomya V, Charuchinda C, Pukanhapan N, Lorvidhaya V: Phase II clinical study of irinotecan and cisplatin as first-line chemotherapy in metastatic or recurrent cervical cancer. Gynecol Oncol 89: 402-407, 2003
21. Frasci G, Comelia P, Thomas R, Di Bonito M, Lapenta L, Capasso I, Botti G, Vallone P, De Rosa V, D'Aiuto G, Comelia G: Biweekly docetaxelirinotecan with filgrastim support in pretreated breast and non-small-cell lung cancer patients. A phase I study. Cancer Chemother Pharmacol 53: 25-32, 2004
22. Sekine I, Nishiwaki Y, Kakinuma R, Kubota K, Hojo F, Matsumoto T, Ohmatsu H, Goto K, Kodama T, Eguchi K, Shinkai T, Tamura T, Ohe Y, Kunitoh H, Yoshimura K, Saijo: Phase I/II trial of weekly cisplatin, etoposide, and irinotecan chemotherapy for metastatic lung cancer. JCOG 9507. Br J Cancer 88: 808-813, 2003
23. Escobar PF, Markman M, Rose P, Zanotti K, Webster K, Belinson J: Phase 2 trial of carboplatin, paclitaxel, and irinotecan in ovarian, fallopian tube, and primary peritoneal cancers. Gynecol Oncol 92: 192-196, 2004
24. Markham C, Stocken DD, Hassan B: A phase II irinotecan-cisplatin combination in advanced pancreatic cancer. Br J Cancer 89: 1860-1864, 2003
25. Fizazi K, Rolland F, Chevreau C, Droz JP, Mery-Mignard D, Culine S, Escudier B: A phase II study of irinotecan in patients with advanced renal cell carcinoma. Cancer 98: 61-65, 2003
26. Shimada Y, Yoshino M, Wakui A, Nakao I, Futatsuki K, Sakata Y, Kambe M, Taguchi T, Ogawa N: Phase II study of CPT-11, a new camptothecin derivative, in metastatic colorectal cancer. CPT-11 Gastrointestinal Cancer Study Group. J Clin Oncol 11: 909-913, 1993
27. Rougier P, Bugat R, Douillard JY, Culine S, Suc E, Brunet P, Becouarn Y, Ychou M, Marty M, Extra JM, Bonneterre J, Adenis A, Seitz JF, Ganem G, Namer M, Conroy T, Negrier S, Merrouche Y, Burki F, Mousseau M, Herait P, Mahjoubi M: Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy. J Clin Oncol 15: 251-260, 1997
28. Anton A, Aranda E, Carrato A, Marcuello E, Massutti B, Cervantes A, Abad A, Sastre J, Fenandez-Martos C, Gallen M, Diaz-Rubio E, Huarte L, Balcells M: TTD cooperative group: Irinotecan (CPT-11) in metastatic colorectal cancer patients resistant to 5-fluorouracil (5-FU): a phase II study. Methods Find Exp Clin Pharmacol 25: 639-643, 2003
29. Lordick F, von Schilling C, Bernhard H, Hennig M, Bredenkamp R, Peschel C: Phase II trial of irinotecan plus docetaxel in cisplatin-pretreated relapsed or refractory oesophageal cancer. Br J Cancer 89: 630-633, 2003
30. Bass AJ, Gockerman JP, Hammett E, DeCastro CM, Adams DJ, Rosner GL, Payne N, Davis P, Foster T, Moore JO, Rizzieri DA: Phase I evaluation of prolonged-infusion gemcitabine with irinotecan for relapsed or refractory leukemia or lymphoma. J Clin Oncol 20: 2995-3000, 2002
31. Hecht JR: Gastrointestinal toxicity of irinotecan. Oncology (Huntingt) 12(Suppl 6): 72-78, 1998
32. Cats A: New developments in systemic chemotherapy in advanced colorectal cancer. Scand J Gastroenterol (Suppl) 239: 78-86, 2003
33. Darzynkiewicz Z: Apoptosis in antitumor strategies modulation of cell cycle or differentiation. J Cell Biochem 58: 151-159, 1995
34. Christensen JG, LeBlanc GA: Reversal of multiding resistance in vivo by dietary administration of the phytochemical indole-3-carbinol. Cancer Res 56: 574-581, 1996
35. Singh RP, Dhanalakshmi S, Agarwal R: Phytochemicals as cell cycle modulators. Cell Cycle1: 156-161, 2002
36. Sawada N, Kataoka K, Kondo K, Arimochi H, Fujino H, Takahashi Y, Miyoshi T, Kuwahara T, Monden Y, Ohnishi Y: Betulinic acid augments the inhibitory effects of vincristine on growth and lung metastasis of B16F10 melanoma cells in mice. Br J Cancer 90: 1672-1678, 2004
37. Berenbaum MC: Criteria for analyzing interactions between biologically active agents. Adv Cancer Res 35: 269-336, 1981
38. Sora MK, Kruszewski AA, Stoklosa T, Czyzyk J, Lasek W, Malejczyk J, Jakobisiak M: Synergistic antiproliferative activity of tumor necrosis factor alpha (TNF-alpha) and lovastatin. Arch Immunol Ther Exp (Warsz) 42: 269-74, 1994
39. Ohyama H, Shimokawa T: Detection of DNA fragmentation by agarose gel electrophoresis. In: Tsujimoto Y, Tone S, Yamada T, eds. New Techniques in Apoptosis Analysis. Yodosha, Tokyo, 1999, pp.59-66
40. Yang J, Liu X, Bhalla K, Kim CN, Ibrado AM, Cai J, Peng T-I, Jones DP, Wang X: Prevention of apoptosis by Bcl-2: release of cytochrome c from mitochondria blocked. Science 275: 1129-1132, 1997
41. Nicholson DW, Ali A, Thornberry NA, Vaillancourt JP, Ding CK, Gallant M, Gareau Y, Griffin PR, Labelle M, Lazebnik YA, Munday NA, Raju SM, Smulson ME, Yamin T-t, Yu VL, Miller DK: Identification and inhibition of the ICE/CED-3 protease necessary for mammalian apoptosis. Nature 376: 37-43, 1995
42. Liu X, Li P, Widlak P, Zou H, Luo X, Garrard WT, Wang X: The 40-kDa subunit of DNA fragmentation factor induces DNA fragmentation and chromatin condensation during apoptosis. Proc Natl Acad Sci USA 95: 8461-8466, 1998
43. Kluck RM, Bossy-Wetzel E, Green DR, Newmeyer DD: The release of cytochrome c from mitochondria: a primary site for Bcl-2 regulation of apoptosis. Science 275: 1132-1136, 1997
44. Ohmori T, Podack ER, Nishio K, Takahashi M, Miyahara Y, Takeda Y, Kubota N, Funayama Y, Ogasawara H, Ohira T, Ohta S, Saijo N: Apoptosis of lung cancer cells caused by some anticancer agents (MMC, CFT-11, ADM) is inhibited by bcl-2. Biochem Biophys Res Commun 192: 30-36, 1993
45. Nagasawa H, Li CY, Maki CG, Imrich AC, Little JB: Relationship between radiation-induced G1 phase arrest and p53 function in human tumor cells. Cancer Res 55: 1842-1846, 1995
46. Abal M, Bras-Goncalves R, Judde J-G, Fsihi H, de Cremoux P, Louvard D, Magdelenat H, Robine S, Poupon M-F: Enhanced sensitivity to irinotecan by Cdk 1 inhibition in the p53-deficient HT 29 human colon cancer cell line. Oncogene 23: 1737-1744, 2004
47. Arnould S, Guichard S, Hennebelle I, Cassar G, Bugat R, Canal P: Contribution of apoptosis in the cytotoxicity of the oxaliplatin-irinotecan combination in the HT29 human colon adenocarcinoma cell line. Biochem Pharmacol 64: 1215-1226, 2002
48. Hayward RL, Macpherson JS, Cummings J, Monia BP, Smyth JF, Jodrell DI: Antisense Bcl-xl down-regulation switches the response to topoisomerase I inhibition from senescence to apoptosis in colorectal cancer cells, enhancing global cytotoxicity. Clin Cancer Res 9: 2856-2865, 2003
49. Hsu Y-L, Kuo P-L, Lin C-C: Proliferative inhibition, cell-cycle dysregulation, and induction of apoptosis by ursolic acid in human non-small cell lung cancer A 549 cells. Life Sciences 75: 2303-2316, 2004
50. Belcaro GV, Grimaldi R, Guidi G: Improvement of capillary permeability in patients with venous hypertension after treatment with TTFCA. Angiology 4: 533-540, 1990
51. Brinkhaus B, Lindner M, Schuppan D, Hahn EG: Chemical, pharmacological and clinical profile of the East Asian medicinal plant Centella asiatica. Phytomedicine 7: 427-448, 2000